Heidi Health — Funding & Company Data

Heidi Health's funding trajectory demonstrates accelerating momentum and strong investor confidence in the competitive AI medical scribe market. The company, originally launched as Oscer in 2019, began with a $5 million Seed round in 2021 led by Blackbird Ventures. This was followed by a multi-part Series A, including a $10 million raise in late 2023 and a $16.6 million follow-on in March 2025, which brought in new investors like Headline and Anthology.

The company's most significant capital injection was its $65 million Series B in October 2025, led by Point72 Private Investments, which valued the company at $465 million. This round occurred just seven months after its Series A follow-on, signaling rapid growth and market traction that commanded a significant valuation increase. The quality of investors, from Australian VC leader Blackbird to major global players like Point72 and Headline, validates Heidi's technology and go-to-market strategy.

This substantial funding provides Heidi with a considerable runway to execute its ambitious roadmap. The capital is earmarked for global expansion, particularly in the U.S., U.K., and Canada, and for evolving the product from a simple scribe to a comprehensive "AI Care Partner" with features for pre-chart summaries and patient engagement. From a competitive standpoint, this war chest is critical as it competes with other well-funded players like Abridge and Ambience, and incumbents like Epic entering the space. For a potential user, this financial backing signals that Heidi is a well-supported company likely to be a stable, long-term partner.